Industry-Patient-Friendly Tadalafil Oral Spray: Statistical Development, Functionality and In-Vivo Taste Assessment

The current work aimed to design a new patient-friendly Tadalafil (TDL) oral spray for management of erectile dysfunction employing concept of advanced data mining and analytical tools. An inclusion complex of TDL: Dexolve®, was formulated and characterized for its physicochemical properties. Phase solubility study suggested a 1:1 ratio of TDL: Dexolve® showed higher solubility. FTIR, DSC, and XRD studies confirmed the partial alteration of crystalline to amorphous. The complex assessed in-vivo for taste masking inculcating the Brief Access Taste Aversion (BATA) model, indicated the taste masking of TDL. The complex was incorporated into spray formulation using water: ethanol, Vitamin D and HPMC E5. MLRA and ANOVA depicted the crucial correlation between amount of ethanol and HPMC E5 with spray pattern and % TDL release. The results of characterization suggested that it covered the maximum area of the oral cavity, indicated uniform distribution and more absorption. The design batches were evaluated for varied oral spray-related parameters and stability studies. The formulation was found stable and released TDL immediately. Dexolve® was found to be a promising multifunctional excipient. The oral spray prepared was environmentally friendly as it is propellant-free. The newer stable and immediateacting spray improves release of TDL and is patient-friendly.